Mechanism of Action
Melanocortin Receptor Subtypes
Alpha-MSH activates five melanocortin receptor subtypes (MC1R-MC5R) with varying affinity. MC1R activation on melanocytes drives pigmentation and anti-inflammatory signaling. MC3R and MC4R are centrally expressed and mediate appetite suppression, energy expenditure, and fever modulation. MC1R activation on immune cells and endothelial tissue produces the potent anti-inflammatory effects that distinguish alpha-MSH from synthetic melanocortin analogs.
Anti-inflammatory Signaling
MC1R and MC3R activation elevates intracellular cAMP, activating PKA-mediated cascades that suppress IKK and prevent NF-kB translocation. This blocks transcription of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory mediators. Simultaneously, alpha-MSH upregulates IL-10 and promotes anti-inflammatory M2 macrophage polarization, producing broad suppression of inflammation.
Research Summary
Inflammatory Models
AnimalAnimal models of colitis, arthritis, uveitis, and septic shock consistently show alpha-MSH reduces organ damage, lowers cytokine levels, and improves survival. The anti-inflammatory potency rivals that of glucocorticoids in some models without the metabolic side effects of steroids.
Ischemia-Reperfusion Protection
AnimalAlpha-MSH protects against renal, hepatic, and cardiac ischemia-reperfusion injury in animal models. Mechanisms include anti-apoptotic STAT3 activation, reduced neutrophil infiltration, and suppression of pro-inflammatory gene expression during reperfusion.
Calculate your Alpha-MSH dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-inflammatory research | 10-50 mcg | Intranasal 2x daily | Intranasal |
| Systemic inflammation | 0.1-1 mg/kg | Daily | Subcutaneous (animal) |
Alpha-MSH is distinct from Melanotan-2; focus is anti-inflammatory and neuroprotective rather than tanning or sexual effects.
Interactions
Safety Profile
Native alpha-MSH has a well-established endogenous role and short half-life, suggesting inherent safety at physiological doses. Potential effects include transient pigmentation changes via MC1R, mild appetite suppression via MC4R, and modest blood pressure effects. No significant toxicity has been reported in human Phase I studies. Long-term supraphysiological administration safety is not established.
References
- [1]Catania A, et al. The neuropeptide alpha-MSH in host defense and inflammation. Ann N Y Acad Sci. 1999;885:183-187.
- [2]Getting SJ. Targeting melanocortin receptors as potential novel anti-inflammatory therapeutics. Pharmacol Ther. 2006;111(1):1-15.
- [3]Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory, and protective effects in vitro and in vivo. Endocr Rev. 2008.